Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) issued its quarterly earnings data on Thursday. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.34, Analyst Ratings News reports.

Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 2.24% during mid-day trading on Thursday, hitting $24.39. The stock had a trading volume of 20,979 shares. Oncomed Pharmaceuticals has a 52-week low of $12.07 and a 52-week high of $42.34. The stock’s 50-day moving average is $28.33 and its 200-day moving average is $27.09. The company’s market cap is $719.0 million.

OMED has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, March 25th. They now have a $31.60 price target on the stock. Analysts at Mizuho initiated coverage on shares of Oncomed Pharmaceuticals in a research note on Monday, February 10th. They set a “buy” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $40.52.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.